Researchers saw high recurrence risk in oropharyngeal carcinoma patients with human papillomavirus type 16 DNA in their spit samples both before and after treatment.
Roche's Cobas EGFR v2 mutation test will be able to identify advanced NSCLC patients with EGFR mutations who are likely to benefit from the next-generation treatment.
Qiagen posted revenues of $319.5 million compared to $330.8 million in the year-ago period, and beat analysts' consensus estimate on the top and bottom lines.
The firm increased its MDx revenues 7 percent from a year ago and beat the consensus Wall Street estimates on the top and bottom lines.
The lightweight, mobile device was highlighted in an oral presentation at AACC today.
A Senate committee has unanimously approved a bill to require articles resulting from federally funded projects to be made publicly available, according to ScienceInsider.
The US is heading toward another budget showdown, Nature News says.
In Nature this week: mouse genome functional analysis, more sensitive chromatin immunoprecipitation, and more.
The Center for Data Innovation and HealthITNow argue for re-building of genomic research infrastructure.